|
Jul 1
|
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jun 30
|
Sector Update: Health Care Stocks Higher Late Afternoon
|
|
Jun 30
|
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
|
|
Jun 26
|
Sector Update: Health Care Stocks Edge Higher Late Afternoon
|
|
Jun 26
|
Update: Vor Biopharma Shares Rally After Naming New CEO, Licensing Autoimmune Drug From RemeGen
|
|
Jun 26
|
Vor, with new CEO, changes course to target autoimmune disease
|
|
Jun 25
|
Vor Biopharma Licenses Autoimmune Drug From RemeGen, Names New CEO
|
|
Jun 25
|
Vor Bio Announces $175 Million Private Placement
|
|
Jun 25
|
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
|
|
Jun 25
|
Estimating The Fair Value Of Vor Biopharma Inc. (NASDAQ:VOR)
|
|
Feb 13
|
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
|
|
Sep 30
|
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
|
|
May 9
|
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
|
|
May 2
|
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
|
|
Apr 4
|
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
|
|
Mar 29
|
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
|
|
Mar 20
|
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
|
|
Mar 4
|
Vor Bio to Participate in Upcoming Investor Conferences
|
|
Feb 7
|
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
|
Dec 1
|
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|